ClinicalTrials.gg
RecruitingNCT04076150Updated Sep 21, 2022

Safety and Performance Study of the Optimum Transcatheter Aortic Valve

An interventional study of Transcatheter Aortic Valve (TAV) Implantation With The Optimum TAV System in Severe Aortic Stenosis, sponsored by Thubrikar Aortic Valve, Inc.. Recruiting at 1 site in Poland. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by Thubrikar Aortic Valve, Inc. · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2022, 3 years 11 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Aortic Valve Stenosis with a site in Poland — 10 open to participants now, 11 under way, 1 of them phase 3. Aortic Valve Stenosis · Poland.

Planned enrollment
16th of 16
5 · median 169
Started
2022
with 1 other
No phase
14 of 30
4 open now
Primary completion
2022-12
later than 1 of 10 live
Registered
17th of 30
by date

Among the 30 studies in Aortic Valve Stenosis with a site in Poland, this one is the 16th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2022, is one of 14 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 17th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

10 of the 30 studies in Aortic Valve Stenosis with a site in Poland are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Aortic Valve Stenosis with a site in Poland, or all of them as a file.
02

Study summary

The TAVI (Thubrikar Aortic Valve, Inc.) -1 Study: Safety and Performance Study of the Optimum Transcatheter Aortic Valve- First-in-human study to assess feasibility and safety of the Optimum Aortic Valve Implant

Read the detailed description

The purpose of the study is to assess the safety and performance of the Optimum TAV (Transcatheter Aortic Valve) in patients with symptomatic, severe aortic stenosis who are deemed high-risk for SAVR (Surgical Aortic Valve Replacement) or have contraindications or deemed inoperable for SAVR.

03

Conditions studied

  • Severe Aortic Stenosis
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and capable to provide ;
  2. 70 years of age or older;
  3. Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis with one of the following: aortic valve Effective Orifice Area (EAO) ≤ 1.0 cm2 or 0.6 cm2/m2, mean aortic valve gradient ≥35 mmHg or peak aortic valve velocity > 4 m/sec.
  4. Symptomatology due to native aortic stenosis resulting in a (NYHA) functional classification of II or greater.
  5. Aortic valve annular diameter ≥ 21 and ≤ 23mm measured by MSCT (Multi-Slice Computed Tomography).
  6. A STS (Society of Thoracic Surgeons) score ≥ 8; or Logistic EuroScore I ≥ 15; or a determination by the local heart team that the co-morbidities not captured by the STS or EuroScore are expected to increase the operative mortality risk to > 15%.
  7. Geographically available and willing to comply with follow up.

Exclusion criteria

Exclusion Criteria:

  1. Congenital unicuspid or bicuspid aortic valve;
  2. Noncalcified aortic valve;
  3. Valve eccentricity (calcific or otherwise) that in the opinion of the investigator could compromise procedural success;
  4. Severe (Grade 3 to 4) aortic, mitral, or tricuspid valve regurgitation;
  5. Moderate to severe mitral stenosis;
  6. Myocardial infarction within the past 30 days*
  7. Echocardiographic evidence of intracardiac mass, thrombus or vegetation;
  8. (Left Ventricular Ejection Fraction) \< 30%;
  9. Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds of systemic pressure;
  10. Hemodynamic instability requiring inotropic drug therapy within the past 14 days or mechanical support within the past 6 months; *
  11. Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which, in the opinion of the investigator, precludes safe implant delivery;
  12. Blood dyscrasias defined as: acute leukopenia, acute anemia, acute thrombocytopenia, history of bleeding diathesis or coagulopathy;
  13. Patient ineligible for or refuses blood transfusions;
  14. Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity or small vessels) that would preclude passage of catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT;
  15. Gastrointestinal bleeding within the past 30 days; *
  16. Stroke or (TIA) within past 3 months;*
  17. Renal insufficiency as demonstrated by a serum creatinine > 3.0 mg/dL;
  18. End stage renal disease requiring chronic dialysis;
  19. Active infection requiring ongoing treatment;
  20. Need for emergent surgery or intervention other than the procedure;
  21. or to procedural medication(s) and device material(s) (e.g. titanium, nickel, pork) which cannot be adequately pre-medicated;
  22. \< 1 year due to non-cardiac co-morbid conditions;
  23. Currently participating in any other investigational drug or device study;
  24. Patient lacking capacity to provide (history of any cognitive or mental health status that would interfere with study participation)
  25. Subject found to have an (INR) greater than 2.0 right before the procedure.

    • At the time of procedure, if a subject's medical status has changed since enrollment, the subject shall be re-evaluated for eligibility.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Patients Receiving Optimum TAV

    Patients with symptomatic severe aortic stenosis that will be treated via transcatheter aortic valve implantation procedure

    Device: Transcatheter Aortic Valve (TAV) Implantation With The Optimum TAV System

Interventions

  • DeviceTranscatheter Aortic Valve (TAV) Implantation With The Optimum TAV System

    Treating patients with severe symptomatic aortic stenosis via transcatheter aortic valve implantation by implanting the Optimum TAV inside the native diseased valve via a the Precision Catheter. The Optimum TAV and Precision Catheter together are the Optimum TAV System.

    Also known as: Transcatheter Aortic Valve Replacement

06

What researchers measure

Primary outcomes

  1. Device Success

    Valve deployed from delivery system successfully

    Time frame: 30 days

  2. Correct Positioning

    Deploying a single Optimum TAV in the intended anatomical position and confirming via fluoroscopy as determined by the implanting physician

    Time frame: 30 days

  3. Intended Performance of Optimum TAV - Leaflet Function

    Evaluate leaflet function by assessing the effective orifice area (EOA) (units: cm\^2) via echocardiography

    Time frame: 30 days

  4. Intended Performance of Optimum TAV - mean aortic valve gradient

    Evaluate hemodynamics by assessing the mean aortic valve gradient (units: mmHg) via echocardiography

    Time frame: 30 days

  5. Intended Performance of Optimum TAV - peak aortic valve velocity

    Evaluate hemodynamics by assessing the peak aortic valve velocity (units: m/s) via echocardiography

    Time frame: 30 days

  6. Intended Performance of Optimum TAV - Paravalvular Leak

    Evaluate proper valve sealing by assessing paravalvular leak via echocardiography and fluoroscopy. If paravalvular leak is determined, it will be classified as mild, moderate, or severe.

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • John Paul II Hospital, Dept. of Interventional Cardiology
    Kraków, 31-202, Poland
    Recruiting
    • Jaroslaw Trebacz, MD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2022, 7 months after the start.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 7 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2019
First posted
Sep 3, 2019
StartActual
May 18, 2022
Primary completionEst.
Dec 18, 2022
CompletionEst.
May 18, 2027
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04076150
Lead sponsor
Thubrikar Aortic Valve, Inc.
Collaborators
KCRI
Responsible party
Sponsor
First posted
Sep 3, 2019
Start date
May 18, 2022
Primary completion
Dec 18, 2022 (estimated)
Completion
May 18, 2027 (estimated)
Last update
Sep 21, 2022

Study contacts

Mano Thubrikar, PhD
Contact
mano.thubrikar@tavi.us
6106308284

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion